EcoDrugPlus

Neuropeptide Y Receptor Y2

Ensembl ID : ENSATEG00000010048
Gene Symbol: NPY2R
2 Cross references
183 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSATEG00000010819
Gene Symbol: NPY2RL
3 Cross references
176 Possible Orthologues:

Neuroplastin-Like

Ensembl ID : ENSATEG00000015234
Gene Symbol: LOC113166307
2 Cross references
210 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSATEG00000000622
Gene Symbol: NTSR1
3 Cross references
198 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSATEG00000014637
Gene Symbol: NTRK2
1 Cross references
209 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSATEG00000005562
Gene Symbol: NTRK3
1 Cross references
203 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSATEG00000005463
Gene Symbol: NTRK1
1 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSATEG00000014460
Gene Symbol: NTRK2B
1 Cross references
210 Possible Orthologues:

Nicastrin

Ensembl ID : ENSATEG00000017669
Gene Symbol: NCSTN
3 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSATEG00000029164
Gene Symbol: NAMPT
3 Cross references
219 Possible Orthologues:

Nischarin

Ensembl ID : ENSATEG00000002269
Gene Symbol: NISCH
2 Cross references
210 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSATEG00000002771
Gene Symbol: LOC113150157
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).